Upgrade to SI Premium - Free Trial

Biogen (BIIB) PT Raised to $348 at Baird

July 25, 2018 6:40 AM
Baird raised its price target on Biogen (NASDAQ: BIIB) to $348.00 (from $323.00) while maintaining a Neutral rating.Analyst Brian Skorney ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS View Analyst PT Change

Next Articles